Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 301

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 301
---
(112,321)
  
    Accounts payable 
     130,032  
     128,429  
     1,280,560 
  
    Accrued liabilities 
     2,342,593  
     (50,370) 
     44,239 
  
    Operating lease liability 
     (647,503) 
     (121,589) 
     (672,373)
  
    Net cash used in operating activities 
     (12,278,569) 
     (637,400) 
     (5,789,987)

    Cash flows from financing activities: 

    Proceeds from issuance of convertible notes 
     -  
     -  
     605,230 
  
    Issuance costs for convertible notes 
     -  
     -  
     (41,193)
  
    Common stock subscription deposit 
     -  
     -  
     1,875 
  
    Cash proceeds from exercise of common stock options 
     -  
     -  
     5,766 
  
    Proceeds from issuance of Series A Preferred Stock, net of issuance costs 
     6,757,700  
     -  
     - 
  
    Advances from shareholder 
     13,731  
     -  
     - 
  
    Payment of sponsor loans 
     (19,715) 
     -  

    Payments for short term borrowings 
     (402,514) 
     -  

    Proceeds from short-term borrowings, net 
     408,052  
     -  
     - 
  
    Proceeds from share purchases under ELOC, net of issuance costs 
     4,809,703  
     -  
     - 
  
    Proceeds received from sale of Series B Preferred Stock, net of issuance costs 
     418,316  
     -  
     - 
  
    Proceeds received from sale of Series C Preferred Stock, net of issuance costs 
     803,561  
     -  
     - 
  
    Proceeds from Series A preferred warrant exercises 
     938,800  
     -  
     - 
  
    Net cash provided by financing activities 
     13,727,634